JP2016520590A - 治療薬および使用法 - Google Patents
治療薬および使用法 Download PDFInfo
- Publication number
- JP2016520590A JP2016520590A JP2016514989A JP2016514989A JP2016520590A JP 2016520590 A JP2016520590 A JP 2016520590A JP 2016514989 A JP2016514989 A JP 2016514989A JP 2016514989 A JP2016514989 A JP 2016514989A JP 2016520590 A JP2016520590 A JP 2016520590A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- component
- defines
- nsaid
- endometriosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
本PCT特許出願は、その全体が参照により本明細書に明示的に組み込まれる、2013年5月21日出願の米国仮特許出願第61/825,587号明細書の35USC§119(e)の下での利益を主張する。
Claims (26)
- 子宮内膜症または他の疾患を有する、またはその素因のある対象の治療に使用される化合物において、抗炎症薬成分と、プロゲスチン成分およびプロゲステロン成分のうちの少なくとも1つと、を含むことを特徴とする化合物。
- 請求項1に記載の化合物において、前記抗炎症薬成分がさらに、NSAIDを定義することを特徴とする化合物。
- 請求項1に記載の化合物において、丸剤、皮下植え込み可能なペレット、注射可能な液剤、および坐剤のうちの少なくとも1つを定義することを特徴とする化合物。
- 請求項1に記載の化合物において、前記プロゲスチン成分が、ノルエチンドロン、ノルエチノドレル、酢酸ノルエチンドロン、二酢酸エチノジオール、レボノルゲストレル、ノルエチステロン、ノルゲストレル、デソゲストレル、ゲストデン、ノルゲスチメート、ドロスピレノン、ジエノゲスト、ドロスピレノン、ネストロン、酢酸ノメゲストール、およびトリメゲストンのうちの少なくとも1つを定義することを特徴とする化合物。
- 請求項1に記載の化合物において、前記プロゲステロン成分がタナプロゲットを定義することを特徴とする化合物。
- 請求項2に記載の化合物において、NSAID成分が、サリチレート、プロピオン酸誘導体、酢酸誘導体、エノール酸誘導体、フェナム酸誘導体、選択的COX−2阻害剤、およびスルホンアニリドのうちの少なくとも1つを定義することを特徴とする化合物。
- 請求項2に記載の化合物において、前記NSAID成分が、アスピリン、ジフルニサル、サルサレート、イブプロフェン、デキシブプロフェン、ナプロキセン、フェノプロフェン、ケトプロフェン、デキスケトプロフェン、フルルビプロフェン、オキサプロジン、ロキソプロフェン、インドメタシン、トルメチン、スリンダク、エトドラク、ケトロラク、ジクロフェナク、ナブメトン、ピロキシカム、メロキシカム、テノキシカム、ドロキシカム、ロルノキシカム、イソキシカム、エフェナム酸、メクロフェナム酸、フルフェナム酸、トルフェナム酸、セレコキシブ、ロフェコキシブ、バルデコキシブ、パレコキシブ、ルミラコキシブ、エトリコキシブ、フィロコキシブ、ニメスリド、リコフェロンリジンクロニキシネート、ハイパフォリン、ゴマノハグサおよびカルシトリオールのうちの少なくとも1つを定義することを特徴とする化合物。
- 請求項1に記載の化合物において、生物学的成分を含むことを特徴とする化合物。
- 請求項1に記載の化合物において、AMPIONを含むことを特徴とする化合物。
- 請求項1に記載の化合物において、ピロキシカム、スリンダク、およびナブメトンのうちの少なくとも1つを含むことを特徴とする化合物。
- 請求項10に記載の化合物において、200〜400mgの範囲でスリンダクおよび250〜450μgの範囲でノルエチンドロンを含むことを特徴とする化合物。
- 患者のDNAに存在する、少なくとも1つの子宮内膜症変化リスクに関連するバイオマーカー(EAB)を有することが判明している前記患者に、前記患者における子宮内膜症を予防、緩和、または治癒するために、抗炎症薬成分と、プロゲスチン成分およびプロゲステロン成分のうちの少なくとも1つと、を含む化合物を治療有効量で投与する工程を含むことを特徴とする方法。
- 請求項12に記載の化合物において、前記抗炎症薬成分がさらに、NSAIDを定義することを特徴とする化合物。
- 請求項12に記載の方法において、前記患者の前記DNAにおける前記EABの前記存在が、前記患者における子宮内膜症の存在または素因の変化リスクに相関することを特徴とする方法。
- 請求項12に記載の方法において、前記化合物が、丸剤、皮下植え込み可能なペレット、注射可能な液剤、および坐剤のうちの少なくとも1つを定義することを特徴とする方法。
- 請求項12に記載の方法において、前記プロゲスチン成分が、ノルエチンドロン、ノルエチノドレル、酢酸ノルエチンドロン、二酢酸エチノジオール、レボノルゲストレル、ノルエチステロン、ノルゲストレル、デソゲストレル、ゲストデン、ノルゲスチメート、ドロスピレノン、ジエノゲスト、ドロスピレノン、ネストロン、酢酸ノメゲストール、およびトリメゲストンのうちの少なくとも1つを定義することを特徴とする方法。
- 請求項12に記載の方法において、前記プロゲステロン成分がタナプロゲットを定義することを特徴とする方法。
- 請求項13に記載の方法において、前記NSAID成分が、サリチレート、プロピオン酸誘導体、酢酸誘導体、エノール酸誘導体、フェナム酸誘導体、選択的COX−2阻害剤、およびスルホンアニリドのうちの少なくとも1つを定義することを特徴とする方法。
- 請求項13に記載の方法において、前記NSAID成分が、アスピリン、ジフルニサル、サルサレート、イブプロフェン、デキシブプロフェン、ナプロキセン、フェノプロフェン、ケトプロフェン、デキスケトプロフェン、フルルビプロフェン、オキサプロジン、ロキソプロフェン、インドメタシン、トルメチン、スリンダク、エトドラク、ケトロラク、ジクロフェナク、ナブメトン、ピロキシカム、メロキシカム、テノキシカム、ドロキシカム、ロルノキシカム、イソキシカム、エフェナム酸、メクロフェナム酸、フルフェナム酸、トルフェナム酸、セレコキシブ、ロフェコキシブ、バルデコキシブ、パレコキシブ、ルミラコキシブ、エトリコキシブ、フィロコキシブ、ニメスリド、リコフェロンリジンクロニキシネート、ハイパフォリン、ゴマノハグサおよびカルシトリオールのうちの少なくとも1つを定義することを特徴とする方法。
- 請求項12に記載の方法において、前記化合物が生物学的成分を含むことを特徴とする方法。
- 請求項12に記載の方法において、前記化合物がAMPIONを含むことを特徴とする方法。
- 請求項14に記載の方法において、前記EABがSNPのマイナー対立遺伝子を定義することを特徴とする方法。
- 請求項12に記載の方法において、前記化合物が、ピロキシカム、スリンダク、およびナブメトンのうちの少なくとも1つを含むことを特徴とする方法。
- 請求項23に記載の方法において、前記化合物が、200〜400mgの範囲でスリンダクおよび250〜450μgの範囲でノルエチンドロンを含むことを特徴とする方法。
- 患者において避妊の効果が生じるように、抗炎症薬成分と、プロゲスチン成分およびプロゲステロン成分のうちの少なくとも1つと、を含む化合物を治療有効量で前記患者に投与する工程を含むことを特徴とする方法。
- 請求項25に記載の化合物において、前記抗炎症薬成分がさらに、NSAIDを定義することを特徴とする化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361825587P | 2013-05-21 | 2013-05-21 | |
US61/825,587 | 2013-05-21 | ||
PCT/US2014/038601 WO2014189836A1 (en) | 2013-05-21 | 2014-05-19 | Therapeutic and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016520590A true JP2016520590A (ja) | 2016-07-14 |
Family
ID=51934015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016514989A Pending JP2016520590A (ja) | 2013-05-21 | 2014-05-19 | 治療薬および使用法 |
Country Status (9)
Country | Link |
---|---|
US (4) | US9161941B2 (ja) |
EP (2) | EP3943079A1 (ja) |
JP (1) | JP2016520590A (ja) |
KR (1) | KR20160013098A (ja) |
AU (2) | AU2014268779A1 (ja) |
BR (1) | BR112015029056A2 (ja) |
CA (1) | CA2913149A1 (ja) |
MX (1) | MX2015016038A (ja) |
WO (1) | WO2014189836A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8641738B1 (en) | 2004-10-28 | 2014-02-04 | James W. Ogilvie | Method of treating scoliosis using a biological implant |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
MX2015016038A (es) | 2013-05-21 | 2016-03-21 | Predictive Therapheutics Llc | Agente terapéutico y método de uso. |
US10319475B1 (en) | 2014-06-13 | 2019-06-11 | Enigami Systems, Inc. | Method and apparatus for determining relationships between medications and symptoms |
ME03728B (me) | 2015-06-18 | 2021-01-20 | Estetra Sprl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
RS61777B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetrol |
MY195019A (en) | 2015-06-18 | 2023-01-03 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
SI3310345T1 (sl) | 2015-06-18 | 2021-05-31 | Estetra Sprl | Orodisperzibilna tableta, ki vsebuje estetrol |
US11172698B1 (en) | 2016-02-08 | 2021-11-16 | Jeff Nordahl | Pasteurized juice formed from raw cannabis |
US11191794B1 (en) | 2016-02-08 | 2021-12-07 | Jeff Nordahl | Packaged hemp products formed from raw cannabis |
US9955716B1 (en) | 2016-02-08 | 2018-05-01 | Jeff Nordahl | Packaged frozen ice pops of cannabis juice purée |
US11779622B1 (en) | 2016-02-08 | 2023-10-10 | Jeff Nordahl | Packaged raw cannabis powder |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
EP4181941A4 (en) * | 2020-07-14 | 2024-05-01 | Natur Tech Pharmacal Co Ltd | COMPOSITIONS AND THEIR USES |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04178359A (ja) * | 1990-07-01 | 1992-06-25 | Kuraray Co Ltd | テトラサイクリン誘導体 |
JP2004537504A (ja) * | 2001-02-20 | 2004-12-16 | イスラエル インスティテュート フォー バイオロジカル リサーチ | コリン作用アップレギュレーション及び炎症ダウンレギュレーションを共誘導する化合物、並びにその使用 |
JP2006248904A (ja) * | 2005-03-08 | 2006-09-21 | Yoshihiro Futamura | アルファ−リポ酸と多価不飽和脂肪酸の結合体からなるラジカル消去作用を呈する抗炎症剤、それを含有する食品製剤、化粧品製剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050101579A1 (en) * | 2003-11-06 | 2005-05-12 | Shippen Eugene R. | Endometriosis treatment protocol |
US8123787B2 (en) | 2004-10-28 | 2012-02-28 | Ogilvie James W | Method of treating scoliosis using a biological implant |
US8641738B1 (en) | 2004-10-28 | 2014-02-04 | James W. Ogilvie | Method of treating scoliosis using a biological implant |
TW200716129A (en) | 2005-04-28 | 2007-05-01 | Wyeth Corp | Micronized tanaproget, compositions, and methods of preparing the same |
US20080306034A1 (en) | 2007-06-11 | 2008-12-11 | Juneau Biosciences, Llc | Method of Administering a Therapeutic |
US8932993B1 (en) | 2007-06-11 | 2015-01-13 | Juneau Biosciences, LLC. | Method of testing for endometriosis and treatment therefor |
WO2009075838A2 (en) * | 2007-12-10 | 2009-06-18 | Meditrina Pharmaceuticals, Inc. | Treatment of menorrhagia with aromatase inhibitor |
AU2008341138A1 (en) * | 2007-12-20 | 2009-07-02 | Teva Women's Health, Inc. | Dosage regimens and pharmaceutical compositions and packages for emergency contraception |
US9434991B2 (en) | 2013-03-07 | 2016-09-06 | Juneau Biosciences, LLC. | Method of testing for endometriosis and treatment therefor |
MX2015016038A (es) | 2013-05-21 | 2016-03-21 | Predictive Therapheutics Llc | Agente terapéutico y método de uso. |
US20170112881A1 (en) | 2016-01-06 | 2017-04-27 | Predictive Therapeutics, LLC | Method of Treating Endometriosis |
-
2014
- 2014-05-19 MX MX2015016038A patent/MX2015016038A/es unknown
- 2014-05-19 BR BR112015029056A patent/BR112015029056A2/pt not_active Application Discontinuation
- 2014-05-19 EP EP21194777.5A patent/EP3943079A1/en not_active Withdrawn
- 2014-05-19 US US14/281,127 patent/US9161941B2/en active Active
- 2014-05-19 CA CA2913149A patent/CA2913149A1/en not_active Abandoned
- 2014-05-19 AU AU2014268779A patent/AU2014268779A1/en not_active Abandoned
- 2014-05-19 EP EP14801452.5A patent/EP2999474A4/en not_active Withdrawn
- 2014-05-19 WO PCT/US2014/038601 patent/WO2014189836A1/en active Application Filing
- 2014-05-19 KR KR1020157035992A patent/KR20160013098A/ko not_active Application Discontinuation
- 2014-05-19 US US14/281,172 patent/US9149499B1/en active Active
- 2014-05-19 JP JP2016514989A patent/JP2016520590A/ja active Pending
-
2015
- 2015-10-05 US US14/875,656 patent/US10213439B2/en not_active Expired - Fee Related
-
2019
- 2019-01-11 US US16/245,564 patent/US10744143B2/en active Active
- 2019-10-10 AU AU2019246858A patent/AU2019246858A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04178359A (ja) * | 1990-07-01 | 1992-06-25 | Kuraray Co Ltd | テトラサイクリン誘導体 |
JP2004537504A (ja) * | 2001-02-20 | 2004-12-16 | イスラエル インスティテュート フォー バイオロジカル リサーチ | コリン作用アップレギュレーション及び炎症ダウンレギュレーションを共誘導する化合物、並びにその使用 |
JP2006248904A (ja) * | 2005-03-08 | 2006-09-21 | Yoshihiro Futamura | アルファ−リポ酸と多価不飽和脂肪酸の結合体からなるラジカル消去作用を呈する抗炎症剤、それを含有する食品製剤、化粧品製剤 |
Non-Patent Citations (4)
Title |
---|
AMERICAN FAMILY PHYSICIAN, vol. Volume.87, No.2, JPN6018009032, 15 January 2013 (2013-01-15), pages 107 - 113 * |
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 206, no. 3, JPN6019000273, March 2012 (2012-03-01), pages p.253.e1-e9 * |
AMPIO PHARMACEUTICALS PROSPECTUS SUPPLEMENT, JPN6018009039, 20 December 2011 (2011-12-20) * |
FERTILITY AND STERILITY, vol. 83, no. 1, JPN6018009033, January 2005 (2005-01-01), pages 171 - 181 * |
Also Published As
Publication number | Publication date |
---|---|
US9149499B1 (en) | 2015-10-06 |
AU2014268779A1 (en) | 2016-01-21 |
BR112015029056A2 (pt) | 2017-07-25 |
US20140348957A1 (en) | 2014-11-27 |
US10744143B2 (en) | 2020-08-18 |
CA2913149A1 (en) | 2014-11-27 |
KR20160013098A (ko) | 2016-02-03 |
AU2019246858A1 (en) | 2019-10-31 |
US10213439B2 (en) | 2019-02-26 |
EP3943079A1 (en) | 2022-01-26 |
US20190142843A1 (en) | 2019-05-16 |
US20160022696A1 (en) | 2016-01-28 |
US9161941B2 (en) | 2015-10-20 |
WO2014189836A1 (en) | 2014-11-27 |
EP2999474A1 (en) | 2016-03-30 |
MX2015016038A (es) | 2016-03-21 |
EP2999474A4 (en) | 2016-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10744143B2 (en) | Therapeutic and method of use | |
ES2625950T3 (es) | Composición farmacéutica para la anticoncepción de emergencia | |
Joshi | Multimodal analgesia techniques and postoperative rehabilitation | |
Wallace | Recent advances in gastric ulcer therapeutics | |
JP2011105733A5 (ja) | ||
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
SI2529622T1 (en) | Bruton tyrosine kinase inhibitors | |
Klee et al. | Network pharmacology for antiepileptogenesis: tolerability of multitargeted drug combinations in nonepileptic vs. post-status epilepticus mice | |
Lee et al. | Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial | |
Polentarutti et al. | Modification of gastric pH in the fasted dog | |
Singgih et al. | A review of nonsteroidal anti-inflammatory drugs (NSAIDs) medications in dentistry: uses and side effects | |
JP2017529388A5 (ja) | ||
JP2020503269A5 (ja) | ||
TW201811372A (zh) | 利用fxr促效劑之方法 | |
IL198891A (en) | Α2δ and nsaids ligands for use in the treatment of lower urinary tract irregularities | |
Dionne et al. | Use of ibuprofen in dentistry | |
ES2323708T3 (es) | Composiciones farmaceuticas antiinflamatorias para reducir inflamacion y el tratamiento o la prevencion de toxicidad gastrica. | |
JP2020515523A5 (ja) | ||
JP5579958B2 (ja) | Cox−2インヒビターを含有する鎮痛及び抗炎症性組成物 | |
Hawkey et al. | Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis | |
Gargya et al. | NSAIDS (Non-Steroidal Anti-Inflammatory Drugs)-their effects and side effects in orthodontic therapy-a review | |
US20150150888A1 (en) | Combination of selective progesterone-receptor modulators and nonsteroidal anti-inflammatory drugs | |
WO2014117117A1 (en) | Chronic nsaid treatment for fuchs endothelial corneal dystrophy | |
Park et al. | Ketoprofen plaster toxicity induced gastrointestinal hemorrhage in a dog | |
Bekhit et al. | Nonopioid analgesic and adjunct drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180313 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180913 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190115 |